HIGHLIGHTS
- who: Report and collaborators from the Medicine, City University of New York, Bronx, USA have published the research: Review began 06/06/2022 Review ended 06/09/2022 Published 06/10/2022 u00a9 Copyright, in the Journal: (JOURNAL) of June/10,/2022
- what: Given the current widespread use of empagliflozin due to its cardioprotective effects in diabetic and nondiabetic patients, the number of cases of eDKA will continue to rise and can be easily missed, especially in patients who are yet not diagnosed with diabetes.
SUMMARY
Empagliflozin is a sodium-glucose . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.